Chemokeyp: A Feasibility Study for Realtime Safety Data-Capture for Potential Serious Adverse Drug Events
NCT07592234 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2026-05-18
Summary
Chemokeyp is a feasibility study testing a secure ED-Oncology interface for patients receiving chemotherapy who may present to unscheduled care with possible treatment-related complications.
Participants are enrolled through Oncology and issued a medical-alert-style wristband with a QR code. If they attend the Emergency Department, staff can scan the QR code, access a generic study landing page, and, after SVUH authentication, complete a short structured checklist about possible serious adverse events such as infection, chest pain, vomiting, syncope, or other red-flag symptoms.
The platform is designed as a secure research data-capture portal, not an electronic health record or clinical documentation system. It does not read from or write to the hospital EHR, does not provide clinical decision support, and does not change usual clinical care. Data entered by ED clinicians are limited to predefined structured fields for research and safety-signal feasibility purposes.
The study will assess whether ED clinicians can complete the checklist in real time, whether the information can support earlier notification to the research/trial team, and whether this data accurately corresponds with verified serious adverse events. If feasible, Chemokeyp could help improve communication between Oncology, Emergency Medicine, and trial teams, supporting safer care for patients on chemotherapy and informing future development of ED-oncology digital safety tools.
Conditions
- Serious Adverse Events
- Patient Safety
- Pharmacovigilance
- Oncology
Sponsors & Collaborators
-
St Vincent's University Hospital, Ireland
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-02-01
- Primary Completion
- 2026-08-01
- Completion
- 2027-01-01
Countries
- Ireland
Study Locations
More Related Trials
-
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
NCT03498521 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00003703 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
NCT04260802 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies
NCT02326441 ·Status: COMPLETED ·Phase: PHASE1
-
SB-743921 In Patients With Solid Tumors
NCT00136513 ·Status: COMPLETED ·Phase: PHASE1
-
Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00714181 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
NCT02552953 ·Status: COMPLETED ·Phase: PHASE1
-
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors
NCT02688101 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
NCT04999969 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
NCT04827810 ·Status: RECRUITING ·Phase: PHASE1
-
M6620 First in Human Study
NCT02157792 ·Status: COMPLETED ·Phase: PHASE1
-
Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017
NCT00881569 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Cobimetinib in Participants With Solid Tumors
NCT00467779 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
NCT02391480 ·Status: COMPLETED ·Phase: PHASE1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
NCT05055609 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
NCT06710379 ·Status: RECRUITING ·Phase: PHASE1
-
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
NCT00004065 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors
NCT00728793 ·Status: COMPLETED ·Phase: PHASE1
-
A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)
NCT00632931 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients
NCT00473577 ·Status: COMPLETED ·Phase: PHASE1
-
ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
NCT02551185 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
NCT00697632 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
NCT07422610 ·Status: RECRUITING ·Phase: PHASE1